Appendix B: Drug Characteristics Tables

Characteristics of the CCR5 Antagonist

Appendix B, Table 8. Characteristics of the CCR5 Antagonist
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendationsa Serum Half-Life Elimination/
Metabolic Pathway
Adverse Eventsb
Maraviroc
(MVC)
Selzentry
Selzentry:
  • 150 and 300 mg tablets
Selzentry:
  • MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r)
  • MVC 300 mg PO twice daily when given with NRTIs, T-20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers
  • MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)
Take MVC without regard to meals.
14–18 hours CYP3A4 substrate Abdominal pain

Cough

Dizziness

Musculoskeletal symptoms

Pyrexia

Rash

Upper respiratory tract infections

Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions

Orthostatic hypotension, especially in patients with severe renal insufficiency
a For dose adjustment in patients with hepatic insufficiency, see Appendix B, Table 10.
b Also see Table 17.

Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir

Appendix B: Drug Characteristics Tables

Characteristics of the CCR5 Antagonist

Appendix B, Table 8. Characteristics of the CCR5 Antagonist
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendationsa Serum Half-Life Elimination/
Metabolic Pathway
Adverse Eventsb
Maraviroc
(MVC)
Selzentry
Selzentry:
  • 150 and 300 mg tablets
Selzentry:
  • MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r)
  • MVC 300 mg PO twice daily when given with NRTIs, T-20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers
  • MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)
Take MVC without regard to meals.
14–18 hours CYP3A4 substrate Abdominal pain

Cough

Dizziness

Musculoskeletal symptoms

Pyrexia

Rash

Upper respiratory tract infections

Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions

Orthostatic hypotension, especially in patients with severe renal insufficiency
a For dose adjustment in patients with hepatic insufficiency, see Appendix B, Table 10.
b Also see Table 17.

Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir
Updated
Reviewed
Dec. 18, 2019

Download Guidelines